for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eli Lilly And Co

LLY.N

Latest Trade

143.59USD

Change

0.79(+0.55%)

Volume

607,613

Today's Range

142.38

 - 

144.08

52 Week Range

101.41

 - 

170.75

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
142.80
Open
143.20
Volume
607,613
3M AVG Volume
69.55
Today's High
144.08
Today's Low
142.38
52 Week High
170.75
52 Week Low
101.41
Shares Out (MIL)
956.47
Market Cap (MIL)
139,759.50
Forward P/E
20.10
Dividend (Yield %)
2.03

Next Event

Eli Lilly and Co at HMG Live Houston CIO Executive Leadership Summit

Latest Developments

更多

Lilly Announces Agreement To Acquire Disarm Therapeutics

Lilly Statement On NIAID Decision To Pause Enrollment In Activ-3 Clinical Trial

Eli Lilly Says Mirikizumab Shows Continued Symptom Improvement In Patients With Crohn's Disease In Phase 2 Trial

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eli Lilly And Co

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment develops, manufactures and markets products for both food animals and companion animals. The Company's human pharmaceutical products include endocrinology products, neuroscience products, oncology products, immunology products and cardiovascular products. The Company's animal health products segment includes products for food animals and products for companion animals. As of December 31, 2018, the Company manufactured and distributed its products through facilities in the United States, Puerto Rico and 14 other countries.

Industry

Biotechnology & Drugs

Contact Info

Lilly Corporate Ctr

Drop Code 1094, Lilly Corporate Ctr

INDIANAPOLIS, IN

46285-0001

United States

+1.317.2762000

https://www.lilly.com/

Executive Leadership

David A. Ricks

Chairman of the Board, President, Chief Executive Officer

Joshua L. Smiley

Chief Financial Officer, Senior Vice President

Aarti Shah

Senior Vice President - Chief Information and Digital Officer

Daniel M. Skovronsky

Senior Vice President, Chief Scientific Officer and President, Lilly Research Laboratories

Melissa Stapleton Barnes

Senior Vice President - Enterprise Risk Management and Chief Ethics and Compliance Officer

Key Stats

2.33 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

22.9K

2018

24.6K

2019

22.3K

2020(E)

23.9K
EPS (USD)

2017

4.280

2018

5.550

2019

6.040

2020(E)

7.274
Price To Earnings (TTM)
23.77
Price To Sales (TTM)
6.09
Price To Book (MRQ)
34.15
Price To Cash Flow (TTM)
20.42
Total Debt To Equity (MRQ)
398.94
LT Debt To Equity (MRQ)
368.06
Return on Investment (TTM)
19.88
Return on Equity (TTM)
13.93

Latest News

Latest News

GLOBAL MARKETS-World stocks pause rally on J&J news, dollar bounces from 3-week low

The dollar rose from a three-week low on Tuesday while U.S. and European shares eased, as news of pauses in trials of a COVID-19 vaccine and a treatment led investors to take stock of recent rallies before chasing further gains.

FOREX-Dollar strengthens as vaccine, stimulus hopes dim

* Euro, sterling fall against dollar * U.S. dollar index up on stimulus doubts, vaccine uncertainty * Graphic: World FX rates in 2020 https://tmsnrt.rs/2RBWI5E (Adds Eli Lilly drug trial details, updates prices) By Chuck Mikolajczak NEW YORK, Oct 13 (Reuters) - The U.S...

Eli Lilly signs deal for supply of COVID-19 treatments to low income countries

Eli Lilly and Co said on Thursday it had entered into an agreement with the Bill & Melinda Gates Foundation for potential supply of its experimental antibody treatments for COVID-19 to low and middle-income countries. (Reporting by Manas Mishra in Bengaluru; Editing by Shailesh...

Eli Lilly applies for FDA emergency use authorization for COVID-19 treatment

Eli Lilly and Co said on Wednesday it had submitted a request to the U.S. Food and Drug Administration for emergency use of its experimental antibody treatment for COVID-19.

Eli Lilly's rheumatoid arthritis drug helps recovery in COVID-19 patients

Eli Lilly and Co said on Monday its rheumatoid arthritis drug Olumiant helped reduce the time taken to recover from COVID-19 in hospitalized patients in a clinical trial.

Eli Lilly starts late-stage study of arthritis drug in COVID-19 patients

U.S. drugmaker Eli Lilly and Co said on Monday it has started a late-stage trial testing its rheumatoid arthritis drug Olumiant in patients hospitalized with COVID-19.

Eli Lilly starts trial of rheumatoid arthritis drug in COVID-19 patients

Eli Lilly and Co on Monday said it was launching a study of its rheumatoid arthritis drug baricitinib in patients hospitalized for COVID-19.

Eli Lilly starts human study of potential COVID-19 treatment

Eli Lilly and Co said on Monday patients have been dosed to test its potential antibody treatment designed to fight COVID-19, caused by the new coronavirus.

Lilly, Junshi Biosciences to start human trials of COVID-19 antibodies

Shanghai Junshi Biosciences Co Ltd said on Tuesday it planned to start clinical studies to test its experimental COVID-19 antibodies, developed with partner Eli Lilly and Co, by the second quarter of the year in the United States and China.

UPDATE 3-U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that could help it fend off competition from Eli Lilly and Co in the market for migraine drugs.

U.S. court rules for Teva in migraine patent dispute with Eli Lilly

Teva Pharmaceutical Industries Ltd on Tuesday won a ruling from a U.S. administrative court that helps preserve its rights to the migraine drug Ajovy.

Eli Lilly to delay new studies due to coronavirus outbreak

U.S. drugmaker Eli Lilly & Co said on Monday it would delay starting new studies and pause enrollment in most ongoing studies due to the coronavirus outbreak.

Eli Lilly does not expect drug shortages due to coronavirus

U.S. drugmaker Eli Lilly and Co said on Tuesday it does not expect the coronavirus outbreak to result in shortages for any of its therapies, including all forms of insulin.

FDA approves Eli Lilly's Trulicity to reduce cardiovascular risks in type 2 diabetic patients

Eli Lilly and Co said on Friday the U.S. Food and Drug Administration has approved Trulicity for reducing cardiovascular risk factors in type 2 diabetic patients.

UPDATE 3-Eli Lilly to add eczema drug with $1.1 bln deal for Dermira

Eli Lilly and Co said on Friday it would buy skin disease specialist Dermira Inc for about $1.1 billion in cash, bolstering its arsenal with an experimental therapy for skin condition atopic dermatitis.

Eli Lilly expects higher-than-expected 2020 profit

Eli Lilly and Co on Tuesday forecast a higher-than-expected profit for 2020, citing growing demand for its medicines including diabetes drug Trulicity and psoriatic arthritis treatment Taltz.

UPDATE 2-FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

FDA panel votes against Lilly-Boehringer Ingelheim's diabetes drug

Independent experts on an FDA advisory panel on Wednesday voted against the use of an already approved diabetes drug from Eli Lilly and Co and Boehringer Ingelheim as an add-on to insulin therapy in patients with type 1 diabetes.

Eli Lilly to target cancer drug developers for deals

Eli Lilly and Co will target cancer drug developers for deals, Chief Executive Officer Dave Ricks said on a post-earnings conference call on Wednesday.

Eli Lilly reports 9% rise in third-quarter profit

Eli Lilly and Co reported a 9.1% increase in third-quarter profit on Wednesday, helped by higher sales of its top-selling diabetes drug, Trulicity, and lower tax expense.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up